23.08.2018
Heidelberg Pharma AG DE000A11QVV0
DGAP-News: Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
DGAP-News: Heidelberg Pharma AG / Key word(s): Alliance/Study
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial
for Kidney Cancer Imaging in Europe
23.08.2018 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial
for Kidney Cancer Imaging in Europe
Ladenburg, Germany, 23 August 2018 - Heidelberg Pharma AG (ISIN DE000A11QVV0
/ WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals
Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application
(CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab
(TLX250) for the imaging of renal (kidney) cancer with Positron Emission
Tomography (PET).
The study - referred to as ZIRCON ("Zirconium Imaging in Renal Cancer
Oncology,
EudraCT 2018-002773-21) - will be a global multi-center Phase III study with
15 sites in Europe, up to 4 sites in Australia and 6 to 8 sites in the US,
subject to regulatory approval in the various jurisdictions. ZIRCON is a
prospective imaging study in approximately 250 kidney cancer patients
undergoing kidney surgery and will determine the sensitivity and specificty
of TLX250 PET imaging to detect clear cell renal cell cancer (ccRCC) in
comparison with histologic "ground truth" determined from surgical resection
specimens. The trial is expected to take 9 to12 months to fully recruit.
Dr. Jan Schmidt-Brand, CEO/CFO of Heidelberg Pharma, said: "We warmly
congratulate Telix on getting to this important stage of development so
quickly. We believe that TLX250 has the potential to truly address a major
unmet medical need by more accurately diagnosing a population of kidney
cancer patients who are frequently mis-staged, which can lead to suboptimal
treatment. We look forward to seeing this program advance through
development and hopefully onto the market."
In January 2017, Heidelberg Pharma granted Telix exclusive worldwide rights
for the development and commercialization of the imaging agent REDECTANE(R),
now called TLX250, a radiolabelled form of the monoclonal antibody
girentuximab. As part of its optimization work, Telix has replaced the
radioisotope Iodine 124 with Zirconium 89, which is expected to allow for
even higher resolution images, lower production costs and a more streamlined
clinical workflow.
Telix CEO, Dr. Christian Behrenbruch, stated, "The filing of this clinical
trial in Europe marks a major milestone for the company in terms of
realizing the value of our product pipeline. We'd like to express our
appreciation to our partner Heidelberg Pharma for the practical support over
the last 18 months in terms of getting this program launched, as well as our
academic collaborators in the US, Australia and Europe."
Under the terms of the agreement with Telix, Heidelberg Pharma is eligible
to receive upfront and milestone payments totaling USD 3.7 million. The
approval of the CTA to initiate the Phase III trial in Europe with TLX250
will trigger a development milestone payment to Heidelberg Pharma.
Heidelberg Pharma also is eligible to receive double-digit royalties on
global net sales. Telix is responsible for all development costs, as well as
manufacturing and commercialization costs of girentuximab, for both
diagnostic and therapeutic applications.
Further details can be found in Telix's recent press release at
http://www.telixpharma.com.
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg,
Germany. Heidelberg Pharma is an oncology specialist and the first company
to develop the toxin Amanitin into cancer therapies using its proprietary
Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the
biological mode of action of the toxin as a novel therapeutic principle.
This proprietary technology platform is being applied to develop the
Company's proprietary therapeutic ATACs, as well as in third-party
collaborations, to create a variety of ATAC candidates. The proprietary lead
candidate is HDP-101, a BCMA ATAC for multiple myeloma.
The Company has entered into partnerships to further develop and
commercialize its clinical assets MESUPRON(R) and REDECTANE(R), while
RENCAREX(R) is available for out-licensing and further development.
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
www.heidelberg-pharma.com.
Contact Heidelberg Pharma AG IR/PR support MC Services AG
Sylvia Wimmer Tel.: +49 89 41 31 Katja Arnold (CIRO) Managing
38-29 Email: Director & Partner Tel.: +49 89
investors[at]hdpharma.com 210 228-40 Email:
Schriesheimer Str. 101, 68526 katja.arnold[at]mc-services.eu
Ladenburg
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to place
undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
---------------------------------------------------------------------------
23.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: [email protected]
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
716675 23.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Heidelberg Pharma AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6